Liver Fat Assessment with Body Shape.

Annu Int Conf IEEE Eng Med Biol Soc

Published: July 2022

Hepatic steatosis has become a serious health concern among the general population, but especially for those who are obese. Liver fat can increase the risk of cirrhosis and even liver cancer. Current standard methods to assess hepatic steatosis, such as liver biopsy and CT/MR imaging techniques, are expensive and/or may have associated risks to health. In this paper, we use body shapes to assess hepatic steatosis using both traditional linear regression models and a deep neural network. We apply our models to a medical dataset and evaluate the approaches for both regression and classification. We compare the performance of several models via popular evaluation metrics. The experimental results indicate that our proposed neural network outperforms the vanilla linear regression model by 22.37% in RMSE and the accuracy by 18%. The R-squared value of the neural model is more than 0.72 and the accuracy reaches 78%. Hence, the body shape features can provide an additional accurate and affordable choice to monitor the degree of the patient's liver fat. Clinical relevance - This paper presents a low cost and convenient approach to predict liver fat percentage using body shapes. This approach will not replace the gold standard for assessing hepatic steatosis. However, with the wide availability for depth cameras (including on smartphones), the approach promises to provide another modality that can be deployed widely in clinical setting as well for home use for telehealth.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329563PMC
http://dx.doi.org/10.1109/EMBC48229.2022.9871321DOI Listing

Publication Analysis

Top Keywords

liver fat
16
hepatic steatosis
16
body shape
8
assess hepatic
8
body shapes
8
linear regression
8
neural network
8
liver
6
fat assessment
4
body
4

Similar Publications

South Asia has high prevalence rates of type 2 diabetes (T2D). Until the 1990s, the prevalence of T2D within South Asia was low but much higher in the South Asian diaspora living abroad. Today, high prevalence rates of T2D are reported among those living in South Asia.

View Article and Find Full Text PDF

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver condition characterized by excessive hepatic fat accumulation. Early diagnosis is crucial as NAFLD can progress to more severe conditions like steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma without timely intervention. While liver biopsy remains the gold standard for NAFLD assessment, abdominal ultrasound (US) imaging has emerged as a widely adopted non-invasive modality due to convenience and low cost.

View Article and Find Full Text PDF

Cardiac allograft vasculopathy (CAV) remains a significant challenge after heart transplantation, necessitating effective surveillance methods. This review centers around the role of coronary computed tomography angiography (CCTA) in CAV surveillance, given its unique capabilities to visualize and quantify CAV in comparison with other imaging modalities, including invasive coronary angiography and intravascular ultrasound. CCTA has shown good diagnostic performance for detecting and monitoring CAV, exemplified by a higher sensitivity and negative predictive value compared with invasive coronary angiography.

View Article and Find Full Text PDF

Nonpharmacological Childhood Obesity Management in Denmark Reduces Steatotic Liver Disease and Obesity.

Child Obes

January 2025

Department of Pediactrics, The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Copenhagen University Hospital Holbæk, Holbæk, Denmark.

Steatotic liver disease (SLD) represents a multisystem disease and is a common complication of childhood obesity. We studied fat content at the abdominal level (liver, subcutaneous, and visceral) and the response to childhood obesity management. In this retrospective longitudinal study, 8-18-year-olds with a body mass index (BMI) z-score above 1.

View Article and Find Full Text PDF

Targeting immune cellular populations and transcription factors: unraveling the therapeutic potential of JQF for NAFLD.

Front Immunol

January 2025

Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Background: Non-alcoholic fatty liver disease (NAFLD) constitutes the most prevalent chronic liver disease worldwide. Progression to non-alcoholic steatohepatitis (NASH), the immune cell reservoir within the liver undergoes remodeling, exacerbating liver inflammation and potentially leading to liver fibrosis. Jiangtang Qingre Formula (JQF) is an effective prescription for the clinical treatment of NAFLD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!